The results of bioinformatics analysis illustrated that the risk score better reflected the prognosis, immune infiltration, CNV mutation and drug sensitivity of GC patients, indicating that the MT2A, NOTCH1 and SLC7A5 were the potential targets for oxaliplatin resistance in GC. Here, MT2A is linked to gastric cancer.